Male fruit flies (and humans) have half the number of X chromosomes that females have, yet the expression of X-linked proteins in males is the same because of a sex-specific compensatory mechanism. In this issue of Cell, Beckmann et al. (2005) report that a unique two-stage translation silencing mechanism thwarts synthesis of a male-specific transcription activator in female flies, ensuring that gene dosage compensation occurs only in males.
Male fruit flies (and humans) have half the number of X chromosomes that females have, yet the expression of X-linked proteins in males is the same because of a sex-specific compensatory mechanism. In this issue of Cell, Beckmann et al. (2005) report that a unique two-stage translation silencing mechanism thwarts synthesis of a male-specific transcription activator in female flies, ensuring that gene dosage compensation occurs only in males.
The evolution of sex has been accompanied by an unequal distribution of sex chromosomes in females and males. Selection pressure to equalize the expression of sex-linked genes has driven the evolution of gene dosage compensation mechanisms. Surprisingly, individual species have evolved radically different solutions to the same problem. In mammals, dosage compensation is mediated by inactivation of one of the two X chromosomes in females (Meller and Kuroda, 2002); in the worm C. elegans, it is mediated by partial inactivation of both X chromosomes in hermaphrodites; and in the fruit fly Drosophila melanogaster, compensation requires hypertranscription of the single X chromosome in males. In this issue of Cell, Beckmann et al. (2005) provide convincing evidence for a two-stage translational silencing mechanism in fruit flies which ensures that dosage compensation is limited to males.
In Drosophila, gene dosage compensation is mediated by a heteromultimeric dosage compensation complex (DCC) containing five proteins-male-specific lethal (msl)-1, -2, and -3, maleless (mle), and males absent on the first (mof)-as well as two noncoding RNAs, RNA on the X-1 and X-2 (roX1 and roX2). The DCC binds to several dozen positions along the single X chromosome in males then spreads so that it coats nearly the entire chromosome. This process is thought to "loosen" chromatin structure by mof-mediated acetylation of histone H4 at lysine 16. In this way, the transcription machinery gains access to the promoters of X-linked genes resulting in hypertranscription of the single male X chromosome. DCC formation is regulated by a sex-specific pathway. In female flies, the DCC is not formed due to absence of the essential msl-2 protein. Indeed, ectopic expression of msl-2 in females leads to severe developmental and viability defects due to global overexpression of X-linked genes. Expression of the msl-2 gene is regulated by the master controller of dosage compensation (and sex determination), Sexlethal (SXL), a female-specific protein standing atop this hierarchy (Figure 1) . Expression of functional SXL is ensured in females and suppressed in males through a pathway that directs preferential transcription from sex-specific promoters and transduces the primary genetic X:A (autosome) signal.
SXL is a multifunctional RNA binding protein that plays an important role in several sex-specific regulatory events. SXL expression from a female-specific early promoter drives a positive feedback loop in which SXL directs splicing of its own RNA to produce the functional protein; the absence of SXL in males results in expression of an inactive truncated protein. Thereafter, SXL binds to an intron in the 5#-untranslated region (UTR) of the msl-2 RNA in females, causing retention of the intron, which is spliced out in males. Subsequent binding of SXL to poly(U) stretches in this intron and in the 3#-UTR of msl-2 RNA causes strong repression of msl-2 translation in female flies (Bashaw and Baker, 1997; Kelley et al., 1997). Robust repression of msl-2 translation requires occupancy of both SXL binding sites, and mutation of either of these crucial sites is lethal (Bashaw and Baker, 1997).
The nature of the cooperation between SXL proteins bound to opposite ends of the msl-2 transcript has remained mysterious. In an elegant series of experiments described in this issue, Matthias Hentze and his colleagues have taken a major step toward answering this question (Beckmann et al., 2005) . Taking advantage of a cell-free translation system derived from Drosophila embryos that recapitulates the critical features of eukaryotic mRNA translation, these investigators show that the SXL proteins bound to the 5#-and 3#-UTR use different and independent silencing mechanisms. SXL bound to the 3#-UTR inhibits the stable association of the 43S preinitiation complex with msl-2 RNA, a finding consistent with previous work (Gebauer et al., 2003) . In contrast, SXL bound to the 5#-UTR acts on ribosomal subunits that bypass the earlier block, stalling the 43S complexes upstream of the SXL binding site and before the initiator codon, AUG. Thus, SXL imposes a unique two-stage blockade of translation initiation, causing robust repression of msl-2 protein synthesis. The authors describe the inhibition as a "fail-safe" mechanism. However, this term actually understates the critical importance of the two-component, sequential blocking system. Fail-safe implies that a failure of one component does not result in failure of the system, usually due to the presence of a redundant or compensatory mechanism. In female flies, mutation of either of the two crucial SXL binding sites permits sufficient translation of msl-2 mRNA to cause lethality. Thus, the twostage regulation by SXL may be more appropriately termed "leak-proof," which emphasizes the requisite, near-total repression of msl-2 translation. The evolution of this stringent mechanism of dosage compensation is consistent with the concept, first proposed by Herman 
